Navigation Links
New data showed Actos prevented progression of atherosclerotic plaque volume in patients
Date:3/31/2008

Chicago, IL, March 31, 2008 New data from a clinical trial using intravascular ultrasound (IVUS) technology found that in patients living with type 2 diabetes, ACTOS® (pioglitazone HCl) reduced the atherosclerotic burden in the coronary arteries compared to glimepiride, and prevented progression compared to baseline. These data stem from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial.

The PERISCOPE trial was presented today as a late breaker at the 57th Annual Scientific Session of the American College of Cardiology in Chicago. This trial adds to the body of cardiovascular data for ACTOS. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS, said David P. Recker, M.D., senior vice president, Clinical Sciences and interim president at Takeda Global Research & Development. While not definitive, data from PERISCOPE combined with results from a previous study, looking at surrogate endpoints, have shown a consistent trend toward decreasing cardiovascular risk by reducing the atherosclerotic burden in people with type 2 diabetes.

PERISCOPE is the first clinical trial to examine the effects of an oral antidiabetic medication on the development of coronary atherosclerosis in patients with type 2 diabetes using IVUS technology. The trial conducted in 97 centers in the U.S., Canada and Latin America with 543 patients, used IVUS imaging of the coronary arteries. The analysis demonstrated a statistically significant difference in percent change in coronary artery atheroma volume in favor of ACTOS treatment compared to glimepiride t
'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
917-865-6688
Takeda Pharmaceuticals North America
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
2. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
3. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
4. New study of Concerta showed significant improvement of ADHD symptom management in adults
5. African Americans at Risk for Low Calcium Intake - New Survey Finds Those Experiencing Symptoms of Lactose Intolerance May be Sidelining Dairy in Their Diets
6. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
7. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
8. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
9. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
10. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
11. One third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned company ... absorbent products. The company has recently made efforts ... Tranquility® Premium Protection absorbent products. The company has ... packaging a new look, and is currently working on ... public. , The new website, developed with Thread Marketing ...
(Date:10/20/2014)... October 20, 2014 Succeed is proud to ... companies who participated in the Every Body Walk! ... public awareness project that encourages workers to be more active ... 10,000 Program, which concluded at the end of September, was ... cities and metro areas. Participating companies gave their staff ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... , ... products and services provider DHS Technologies LLC recently revealed its newest shelter system – ... ... Technologies LLC recently revealed its newest shelter system – the Reeves Mobile Vaccination System., ...
... ... income in the current economy, and who are looking to better their health, too, can ... enlisting interested business leaders nationwide., , ... (PRWEB) March 16, 2010 -- Independent businessman Brad Aspin and leading health and wellness ...
... Large amounts of frozen plasma are being used inappropriately, ... Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj081933.pdf ... the clinical use of red blood cells and platelets ... of frozen plasma. "Two recent studies in Canada ...
... ... ... SAN RAFAEL, Calif. , March 15 The following was released today by the Marin Institute: , ... , , ...
... March 15 Spotlighting the importance of oral health care for expectant mothers, the California Dental Association (CDA) Foundation has released new guidelines designed to emphasize the safety of ... ... ... ...
... , March 15 The Board of Directors of Healthcare Trust of America, Inc. ("HTA"), ... June 2010 .  These distributions will be calculated based on the stockholders of record each day ... $10.00 . , ... ...
Cached Medicine News:Health News:DHS Technologies Unveils New Mobile Vaccination System 2Health News:Brad Aspin and Health and Wellness Company GBG Now Looking for Leaders Nationwide 2Health News:Advocates Rally Southland Assembly Health Committee Members to Pass AB 1694 2Health News:Advocates Rally Southland Assembly Health Committee Members to Pass AB 1694 3Health News:Advocates Rally Southland Assembly Health Committee Members to Pass AB 1694 4Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 2Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 4Health News:Healthcare Trust of America Board of Directors Declares Distributions 2Health News:Healthcare Trust of America Board of Directors Declares Distributions 3
(Date:10/17/2014)... 2014  Amgen (NASDAQ: AMGN ) today ... M.D., president of Gladstone Institutes and Gladstone,s Robert W. ... "We are pleased to welcome Dr. Sandy Williams ... Bradway , chairman and chief executive officer of Amgen. ... and his direct experience in our industry will both ...
(Date:10/17/2014)... DALLAS , October 17, 2014 /PRNewswire/ ... research report "Optical Imaging Market by Technique (Optical ... System, Imaging software) & by Application (Ophthalmology, Neurology, Oncology, ... by MarketsandMarkets, this report studies the Optical Imaging ... The market was valued at $917.1 million ...
(Date:10/17/2014)... Md. , Oct. 17, 2014 ... for Medical Technology Policy: The Green ... the FDA, public and private payers, medical device ... clinicians, and other experts January 12, 2015 at ... and value of weight loss treatments.  Participants will ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... A new study by researchers from Children,s Mercy ... that rapid electronic review of children,s heart images by ... and treatment of potentially serious pediatric heart problems. The ... National Conference and Exhibition in San Francisco. ...
... LAKES, N.J., Oct. 4 Medco Health Solutions, ... announce its third-quarter 2010 financial results in a ... November 2, 2010.   (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... release, management will hold a conference call at ...
Cached Medicine Technology:New Study Shows Telemedicine Works to Effectively Identify Heart Problems in Children Far from a Specialized Medical Center 2Medco Announces Date for Third-Quarter 2010 Financial Results 2
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... national reference laboratory and a laboratory ... an extensive test menu of highly ... clinical and anatomic pathology. Owned by ... clients include university teaching hospitals and ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Medicine Products: